Dr. Leisha Emens of UPMC Hillman Cancer Center is joined by breast cancer veteran, Barbara Bigelow, to discuss current immunotherapy research for breast cancer. #bcsm #CRIsummit #immunotherapy summit.cancerresearch.org/
00:00- Tamron Hall introduces Dr. Leisha Emens and Barbara Bigelow
00:48- Dr. Emens discusses breast cancer and immunotherapy
08:29- Barbara leads a Q&A from the audience with Dr. Emens
Breast cancer is one of the most diagnosed cancers among women, with an estimated 2.1 million new cases of breast cancer globally each year. Immunotherapy for breast cancer is developing rapidly following the first FDA-approved checkpoint inhibitor for triple-negative breast cancer in March 2019. New treatment regimens combining immunotherapy with chemotherapy, radiation, or surgery are showing promise in clinical trials. www.cancerresearch.org/Immuno...
Questions from the audience for Dr. Emens:
- If my breast cancer recurs, am I a candidate for immunotherapy?
- What do you think breast cancer treatment will look like in 10 years?
- What’s the industry standard for surveillance after the adjuvant immunotherapy has concluded? What is the time scale for pat or cat scan?
- Can immunotherapy be combined with oncolytic viruses to treat more types of breast cancer?
- How long does immunotherapy have to continue for triple-negative breast cancer? How often are treatments given?
- What is the cut-off for PD-L1 for treatment?
- What are the most promising clinical trials for breast cancer patients?
- If an immunotherapy treatment for triple-negative breast cancer is voluntarily withdrawn, can I still access it?
- What kind of efficacy can you share for triple-negative breast cancer? Is there a recommended duration of immunotherapy treatment for this group?
- Do I need to discontinue my other treatments in order to receive immunotherapy?
- I have autoimmune diseases and metastatic breast cancer. The treatments for these 2 diseases often clash. Would you recommend immunotherapy for someone like me?
- I have an inherited BRCA mutation and a family history of breast cancer. Does this mean I could benefit from immunotherapy if I am diagnosed with cancer?
- Can adoptive cellular therapies, like CAR T cell therapy, be used to treat breast cancer?
- Does immunotherapy treatment affect fertility?
- If side effects are too severe, can I discontinue checkpoint inhibitor immunotherapy for some time and then resume it later?
Dr. Leisha Emens is a professor of medicine, director of translational immunotherapy for the Women’s Cancer Research Center, and co-leader of the Cancer Immunology and Immunotherapy Program at the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center. Dr. Emens is a medical oncologist focused on breast cancer and is internationally recognized for her work in breast cancer immunotherapy.
Barbara Bigelow, Breast Cancer Veteran
Nineteen years ago, Barbara Bigelow was diagnosed with breast cancer. After she finished a treatment regimen of surgery, chemotherapy, and radiation, she decided to have major preventive surgeries to further reduce her risk of recurrence. In 2015, she learned that her cancer had metastasized. After several failed treatments, Barbara enrolled in a cancer immunotherapy clinical trial in January 2016. Despite initially experiencing debilitating side effects, she has been cancer- and treatment-free for five years. www.cancerresearch.org/patien...
The 2021 CRI Virtual Immunotherapy Patient Summit is part of the Cancer Research Institute's Answer to Cancer Patient Education Program. It was offered free of charge, connecting cancer patients and caregivers with scientific and medical experts. This year’s Summit highlighted the growing implications of immunotherapy for more than 10 cancer types, provided education on the basics of immunotherapy and how clinical trials work, and addressed cancer care disparities. www.cancerresearch.org/en-us/...
Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. www.cancerresearch.org
Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.
24 июл 2024
